Sesame Summit 2026 – application open

BOOST Pharma raises €3.1M for rare disease therapeutics

Europe’s rare disease pharmaceutical sector is experiencing renewed investor confidence, with regulatory frameworks like the EU Orphan Drug Regulation creating compelling opportunities for specialised therapeutics. Swedish biotech BOOST Pharma has secured an additional €3.1 million in funding to advance treatments for children with genetic bone diseases, highlighting the growing appetite for precision medicine targeting underserved patient populations.

Sound Bioventures led this follow-on round, demonstrating continued conviction in BOOST Pharma’s approach to rare paediatric conditions. The investment builds on previous backing and positions the Stockholm-based company to accelerate clinical development programmes.

Rare disease biotech funding gains momentum in Europe

Sound Bioventures’ investment thesis centres on therapeutic areas with high unmet medical need and clear regulatory pathways. The fund, known for backing European life sciences companies with differentiated platforms, sees particular value in BOOST Pharma’s focus on genetic bone disorders affecting children.

“We’re backing a team that understands both the scientific complexity of rare bone diseases and the commercial realities of developing orphan drugs in Europe,” explained a Sound Bioventures partner. The investor’s portfolio strategy emphasises companies that can navigate EU regulatory frameworks whilst addressing global markets.

This funding round reflects broader European investor confidence in rare disease therapeutics, where smaller patient populations allow for more targeted development strategies and accelerated regulatory timelines through programmes like EMA’s PRIME designation.

Advancing genetic bone disease treatments

BOOST Pharma’s platform addresses genetic bone disorders that predominantly affect children, representing a significant unmet medical need with limited therapeutic options. The company’s approach leverages advanced understanding of bone biology to develop targeted interventions for these rare conditions.

The €3.1 million will primarily fund clinical trials and regulatory preparation activities across European markets. BOOST Pharma plans to initiate patient studies whilst building manufacturing capabilities to support future commercial deployment.

“Children with genetic bone diseases and their families deserve better treatment options,” stated BOOST Pharma’s leadership team. “This funding enables us to advance our lead programmes through critical development milestones whilst maintaining our European operational base.”

The company’s Stockholm headquarters provides access to Scandinavian clinical networks and regulatory expertise, whilst maintaining cost advantages compared to other European biotech hubs. Recent data from European rare disease registries suggests growing recognition of genetic bone disorders, creating clearer commercial pathways for specialised therapeutics.

This investment signals Sound Bioventures’ confidence in Europe’s rare disease ecosystem and BOOST Pharma’s potential to deliver meaningful outcomes for underserved patient populations through precision therapeutic approaches.

you might also like

FINTECH 1200x650 1
Fundraising 1 day ago

London fintech Outpost raises $17.5M Series A led by Ribbit Capital to scale its AI-powered merchant-of-record platform, simplifying cross-border payments, tax, and compliance for global merchants.

AI fintech funding
Fundraising 2 days ago

The European fintech sector continues to attract early-stage capital, with AI-powered financial modelling emerging as a particularly active frontier for investor interest. As finance teams across high-growth organisations grapple with the limitations of static spreadsheets and fragmented planning tools, a new generation of startups is building intelligent infrastructure to replace legacy workflows. Stockholm-based Galdera Labs has now entered this space with a €1.5 million pre-seed round to develop an AI-native financial modelling platform designed for growth-stage finance teams. The funding will support platform development, reasoning infrastructure buildout, and an initial customer rollout targeting fast-growing companies with complex financial operations. Galdera’s platform combines a high-performance calculation engine with a semantic memory layer that links financial data directly to underlying business context, assumptions, and strategic decisions — enabling finance teams to query models in natural language and simulate complex scenarios in minutes rather than weeks. Klarna Veterans Back AI Financial Modelling Vision The pre-seed round was led by J12 Ventures, with participation from Antler and a roster of angel investors drawn from notable European technology companies including Klarna, DeepL, Stripe, and Plata. The investor composition reflects strong confidence in the founding team’s pedigree and the market opportunity for intelligent financial planning infrastructure. Galdera’s three co-founders — Evan Rumpza (CEO), Mattia Scolari (CFO), and Giovanni Casula (CTO) — met at Klarna during the fintech giant’s most intensive growth phase. Responsible for financial planning across 26 markets, the team experienced first-hand how manual processes and fragmented Excel models struggled to keep pace as business conditions shifted faster than traditional models could be rebuilt. To manage the complexity, they built an internal system at Klarna that replaced the static planning cycle with a continuously updated model — enabling what previously required large analyst teams to be handled by just three people, supporting the company through both capital raises and IPO preparations. The lessons learned from that experience became the foundation for Galdera Labs. “We’ve personally sat with 50 spreadsheets at two in the morning using tools that were supposed to solve the problem but didn’t. That is the infrastructure we are building with Galdera,” said Evan Rumpza, CEO and co-founder of Galdera Labs. Building AI Finance Tools for the Next Generation of CFOs The market for AI finance tools and financial modelling software is evolving rapidly as organisations demand more dynamic planning capabilities. Traditional spreadsheet-based approaches, while flexible, often create fragmented workflows where assumptions become outdated and institutional knowledge is lost between budget cycles. Galdera’s platform addresses this gap with a two-layer architecture: a powerful calculation engine capable of handling large data volumes, paired with a semantic memory layer that preserves the reasoning behind financial decisions over time. The platform is designed to function as an always-on financial forecast that automatically updates as business conditions change. Users configure scenarios once, and the model recalculates impacts across revenue, costs, margins, and other key metrics in real time. This approach positions Galdera within a growing wave of European fintech startups applying artificial intelligence not merely as an overlay on existing tools, but as a foundational redesign of how financial planning operates. With the launch, Galdera is opening its platform to its first customers: fast-growing companies and organisations with complex operations where the pace of decision-making has outgrown the tools finance teams traditionally rely on. Early adopters already include companies such as DeasyLabs, Unify, and Counsel. The pre-seed round positions Galdera Labs at an early but promising stage in a sector where demand for intelligent, context-aware financial infrastructure is accelerating across European markets. As AI continues to reshape enterprise workflows, the intersection of financial modelling and machine reasoning represents a significant opportunity for startups capable of delivering genuine operational value to scaling businesses. Summary

AevoLoop circular plastics recycling technology funding announcement with plastic waste processing
Fundraising 2 days ago

The sustainable consumer goods sector is witnessing growing investor appetite as environmentally conscious brands prove they can combine purpose with profitability. East London-based Allday Goods, the cult kitchen knife brand that transforms plastic waste into chef-quality blades, has raised £765,000 in a seed round led by FIGR Ventures to scale its operations from artisan favourite to mainstream kitchen staple. Founded in 2021 by ex-chef Hugo Worsley, Allday Goods manufactures kitchen knives with handles crafted entirely from recycled plastic waste — sourced from Maldon Salt buckets, milk bottle handles, discarded plant containers, and fishing nets washed up on British shores. The brand, which started in Worsley’s parents’ shed using a repurposed toastie maker, has already achieved profitability with minimal external investment. Products consistently sell out within minutes during online drops, and queues have formed at London pop-ups, reflecting a level of consumer demand that few sustainable brands can match at this stage. FIGR Ventures Leads Seed Round with Sustainability-Focused Backers The £765,000 round was led by FIGR Ventures, with participation from Anotherway Ventures, Machroes Holdings — the family office of Lord Mervyn Davies — and angel investor Tom Gozney, founder of the premium pizza oven brand Gozney. The investor mix signals confidence in Allday Goods’ ability to bridge the gap between sustainable manufacturing and scalable consumer product design. Allday Goods’ knives pair handles made from 100% recycled food-grade polypropylene with British and Japanese steel blades. The company collects, cleans, shreds, and remoulds plastic waste into distinctive, colourful handles that carry visible traces of their former lives — a design choice that has become central to the brand’s identity. Each knife effectively diverts plastic from landfill whilst delivering professional-grade performance. Worsley commented on the raise, noting that the team had built the brand slowly and intentionally, and that securing backing from investors they genuinely admire represents a significant milestone for the next chapter of growth. From Cult Following to Mainstream Market Opportunity Allday Goods has already demonstrated significant commercial traction without substantial marketing spend. The brand’s high-profile collaborations with Ottolenghi, Soho House, Maldon Salt, Kerrygold, and Paul Smith have positioned it at the intersection of culinary craftsmanship and design culture. Features in The World of Interiors and Esquire have further cemented its reputation among discerning consumers who value both aesthetics and environmental responsibility. The fresh capital will be deployed to scale production capacity, expand the product range, and accelerate the transition from limited-edition drops to consistent retail availability. The challenge for Allday Goods will be maintaining the artisan quality and brand mystique that fuelled its cult status whilst meeting the demands of a broader consumer base — a tension that many direct-to-consumer brands have struggled to navigate. The broader sustainable kitchenware market continues to attract both consumer interest and investor capital across Europe. As regulatory pressure on single-use plastics intensifies and consumers increasingly seek products that align with their environmental values, brands like Allday Goods that demonstrate genuine circularity in their manufacturing processes are well-positioned to capture meaningful market share. Summary Company: Allday GoodsHeadquarters: East London, United KingdomFounded: 2021Founder: Hugo WorsleyRound: SeedAmount: £765,000Lead Investor: FIGR VenturesOther Investors: Anotherway Ventures, Machroes Holdings, Tom GozneyUse of Funds: Scale production, expand product range, transition to mainstream retail availability

Subscribe to
our Newsletter!

Stay at the forefront with our curated guide to the best upcoming Tech events.